CoChat

A Combination of Neurofilament Light, Glial Fibrillary Acidic Protein, and Neuronal Pentraxin-2 Discriminates Between Frontotemporal Dementia and Other Dementias

Open access

The DOI matches its Crossref record; 95 of the 95 references it cites were found in a registry or an index; 28 of the 84 sources its claims cite were checked for support.

Abstract

Background: The differential diagnosis of frontotemporal dementia (FTD) is still a challenging task due to its symptomatic overlap with other neurological diseases and the lack of biofluid-based biomarkers. Objective: To investigate the diagnostic potential of a combination of novel biomarkers in cerebrospinal fluid (CSF) and blood. Methods: We included 135 patients from the Center for Memory Disturbances, University of Perugia, with the diagnoses FTD (n = 37), mild cognitive impairment due to Alzheimer’s disease (MCI-AD, n = 47), Lewy body dementia (PDD/DLB, n = 22), and cognitively unimpaired patients as controls (OND, n = 29). Biomarker levels of neuronal pentraxin-2 (NPTX2), neuronal pentraxin receptor, neurofilament light (NfL) and glial fibrillary acidic protein (GFAP) were measured in CSF, as well as NfL and GFAP in serum. We assessed biomarker differences by analysis of covariance and generalized linear models (GLM). We performed receiver operating characteristics analyses and Spearman correlation to determine biomarker associations. Results: CSF NPTX2 and serum GFAP levels varied most between diagnostic groups. The combination of CSF NPTX2, serum NfL and serum GFAP differentiated FTD from the other groups with good accuracy (FTD versus MCI-AD: area under the curve (AUC) [95% CI] = 0.89 [0.81–0.96]; FTD versus PDD/DLB: AUC = 0.82 [0.71–0.93]; FTD versus OND: AUC = 0.80 [0.70–0.91]). CSF NPTX2 and serum GFAP correlated positively only in PDD/DLB (ρ= 0.56, p < 0.05). NPTX2 and serum NfL did not correlate in any of the diagnostic groups. Serum GFAP and serum NfL correlated positively in all groups (ρ= 0.47–0.74, p < 0.05). Conclusion: We show the combined potential of CSF NPTX2, serum NfL, and serum GFAP to differentiate FTD from other neurodegenerative disorders.

Overview

CoChat Summary

TL;DR

A retrospective single-center study found that a cross-matrix panel of CSF NPTX2, serum NfL, and serum GFAP discriminated frontotemporal dementia (FTD) from other dementia groups with AUCs around 0.80–0.89. The authors conclude the combination reflects synaptic, axonal, and astroglial pathology and may aid differential FTD diagnosis, though clinical use is limited by the need for both CSF and serum.

Key findings

  • In 135 patients (FTD n=37, MCI-AD n=47, PDD/DLB n=22, OND n=29), CSF NPTX2 and serum GFAP varied most across diagnostic groups. CSF NPTX2 was lower in all diagnostic groups versus OND, and lowest in PDD/DLB; serum GFAP was higher in MCI-AD than OND, FTD, and PDD/DLB, and higher in FTD and PDD/DLB than OND.
  • The combined model of CSF NPTX2, serum NfL, and serum GFAP differentiated FTD from other groups: FTD versus MCI-AD AUC 0.89 [0.81–0.96], sensitivity 84%, specificity 85%; FTD versus PDD/DLB AUC 0.82 [0.71–0.93], sensitivity 78%, specificity 86%; FTD versus OND AUC 0.80 [0.70–0.91], sensitivity 70%, specificity 83%.
  • CSF NPTX2 and serum GFAP correlated positively only in PDD/DLB (ρ=0.56, p<0.05); serum GFAP and serum NfL correlated positively in all groups (ρ=0.47–0.74, p<0.05). CSF and serum NfL correlated strongly overall (ρ=0.77, p<0.001), while CSF and serum GFAP correlated moderately overall (ρ=0.50, p<0.001).
  • CSF NPTX2 and CSF NPTXR correlated positively with MMSE (ρ=0.41 and ρ=0.33, both p<0.001), while serum NfL and serum GFAP correlated negatively with MMSE (ρ=–0.35 and ρ=–0.49, both p<0.001).

Methods

  • Retrospective inclusion of 135 patients from the Center for Memory Disturbances, University of Perugia, between 2007 and 2018, with diagnoses of FTD, MCI-AD, PDD/DLB, or OND controls; final diagnoses used international criteria, neuropsychological testing, structural imaging, and FDG-PET for suspected FTD.
  • CSF NPTX2, NPTXR, NfL, and GFAP and serum NfL and GFAP were measured by ELISA or Simoa assays; AD CSF biomarkers were used to define A/T/(N) profiles.
  • Analyses included ANCOVA adjusted for age and sex with Tukey post-hoc tests, generalized linear models, ROC analyses, and Spearman correlations, with Bonferroni correction for multiple comparisons.

Limitations

  • Stated: small diagnostic group sizes led to low statistical power; MCI-AD patients were included at the pre-dementia stage rather than dementia, though they converted within 12–18 months of lumbar puncture; the NPTXR ELISA did not meet optimal CSF measurement criteria, so NPTXR granularity may be suboptimal; the proposed combination requires both CSF and serum, while a blood-only panel would be preferred, and serum NPTX2 was not available.
  • Evident from the text: this is a single-center retrospective study without independent replication; the FTD group includes small subtype subgroups; three FTD patients had co-occurring AD pathology (A+/T+), although the authors report main findings were retained after excluding them.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3233/jad-220318

Cites

95 of 95 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Figures

Fig. 1 Biomarker levels across diagnostic groups. A-F) Boxplots showing the level of each candidate biomarker across different diagnostic groups. Lines through the boxes represent the median, and the upper and lower line represent the 25th and 75th percentile, respectively. NPTX2, NfL in serum, and NfL in CSF were log-transformed, and a square-root transformation was applied to GFAP in serum to achieve a normal distribution. Differences in biomarker levels were assessed with age and sex adjusted ANCOVA with Tukey’s post hoc test. *p < 0.05, **p < 0.01, ***p < 0.001. OND, Other neurological diseases; MCI-AD, Mild cognitive impairment due to Alzheimer’s disease; FTD, Frontotemporal dementia; PDD/DLB, Lewy body dementias; CSF, Cerebrospinal fluid; NPTX2, Neuronal pentraxin-2; NPTXR, Neuronal pentraxin receptor; NfL, Neurofilament light; GFAP, Glial fibrillary acidic protein.
Fig. 1 Biomarker levels across diagnostic groups. A-F) Boxplots showing the level of each candidate biomarker across different diagnostic groups. Lines through the boxes represent the median, and the upper and lower line represent the 25th and 75th percentile, respectively. NPTX2, NfL in serum, and NfL in CSF were log-transformed, and a square-root transformation was applied to GFAP in serum to achieve a normal distribution. Differences in biomarker levels were assessed with age and sex adjusted ANCOVA with Tukey’s post hoc test. *p < 0.05, **p < 0.01, ***p < 0.001. OND, Other neurological diseases; MCI-AD, Mild cognitive impairment due to Alzheimer’s disease; FTD, Frontotemporal dementia; PDD/DLB, Lewy body dementias; CSF, Cerebrospinal fluid; NPTX2, Neuronal pentraxin-2; NPTXR, Neuronal pentraxin receptor; NfL, Neurofilament light; GFAP, Glial fibrillary acidic protein.CC BY-NC · PubMed Central
Fig. 2 Association between MMSE score and biomarker levels. Associations between MMSE scores and biomarker levels were assessed using Spearman’s correlation. A, B) MMSE scores correlated positively with NPTX2 in CSF and NPTXR in CSF. C-F) MMSE scores correlated negatively with NfL and GFAP in serum but did not reach significance in CSF. Lines represent linear regression and grey areas represent 95% confidence intervals. MMSE, Mini-mental state examination; CSF, Cerebrospinal fluid; NPTX2, Neuronal pentraxin-2; NPTXR, Neuronal pentraxin receptor; NfL, Neurofilament light; GFAP, Glial fibrillary acidic protein.
Fig. 2 Association between MMSE score and biomarker levels. Associations between MMSE scores and biomarker levels were assessed using Spearman’s correlation. A, B) MMSE scores correlated positively with NPTX2 in CSF and NPTXR in CSF. C-F) MMSE scores correlated negatively with NfL and GFAP in serum but did not reach significance in CSF. Lines represent linear regression and grey areas represent 95% confidence intervals. MMSE, Mini-mental state examination; CSF, Cerebrospinal fluid; NPTX2, Neuronal pentraxin-2; NPTXR, Neuronal pentraxin receptor; NfL, Neurofilament light; GFAP, Glial fibrillary acidic protein.CC BY-NC · PubMed Central
Fig. 3 ROC analysis of combined biomarkers for FTD. Diagnostic performance of the combined biomarkers to differentiate FTD from the other diagnostic groups were assessed with ROC analyses and the corresponding AUC. The combination included CSF NPTX2, serum NfL and serum GFAP, while the basic model only included age and sex as predictor variables. A) FTD versus OND. B) FTD versus MCI-AD. C) FTD versus PDD/DLB. ROC, Receiver operating characteristics; AUC, Area under the curve; FTD, Frontotemporal dementia; OND, Other neurological diseases; MCI-AD, Mild cognitive impairment due to Alzheimer’s disease; PDD/DLB, Lewy body dementias; NPTX2, Neuronal pentraxin-2; NfL, Neurofilament light; GFAP, Glial fibrillary acidic protein.
Fig. 3 ROC analysis of combined biomarkers for FTD. Diagnostic performance of the combined biomarkers to differentiate FTD from the other diagnostic groups were assessed with ROC analyses and the corresponding AUC. The combination included CSF NPTX2, serum NfL and serum GFAP, while the basic model only included age and sex as predictor variables. A) FTD versus OND. B) FTD versus MCI-AD. C) FTD versus PDD/DLB. ROC, Receiver operating characteristics; AUC, Area under the curve; FTD, Frontotemporal dementia; OND, Other neurological diseases; MCI-AD, Mild cognitive impairment due to Alzheimer’s disease; PDD/DLB, Lewy body dementias; NPTX2, Neuronal pentraxin-2; NfL, Neurofilament light; GFAP, Glial fibrillary acidic protein.CC BY-NC · PubMed Central
Fig. 4 Association between combined biomarkers. Associations between the combined biomarkers were assessed using Spearman’s correlation. A) NfL in serum and NPTX2 in CSF showed a weak negative correlation in the whole cohort. B) When stratified for diagnoses, serum and CSF NfL did not correlate in any of the diagnostic groups. C) GFAP in serum and NPTX2 in CSF showed a weak negative correlation in the whole cohort. D) When stratified for diagnoses, GFAP in serum and NPTX2 in CSF correlated positively in PDD/DLB, while no significant correlation was found in OND, FTD, and MCI-AD. E) A significant positive correlation was found for serum GFAP and serum NfL. F) When stratified for diagnoses, a significant positive correlation was found for serum GFAP and serum NfL in OND, FTD, MCI-AD, PDD/DLB. Lines represent linear regression and grey areas represent 95% confidence intervals. CSF, Cerebrospinal fluid; GFAP, Glial fibrillary acidic protein; NPTX2, Neuronal pentraxin-2; NfL, Neurofilament light; OND, Other neurological diseases; FTD, Frontotemporal dementia, MCI-AD, Mild cognitive impairment due to Alzheimer’s disease; PDD/DLB, Lewy body dementias.
Fig. 4 Association between combined biomarkers. Associations between the combined biomarkers were assessed using Spearman’s correlation. A) NfL in serum and NPTX2 in CSF showed a weak negative correlation in the whole cohort. B) When stratified for diagnoses, serum and CSF NfL did not correlate in any of the diagnostic groups. C) GFAP in serum and NPTX2 in CSF showed a weak negative correlation in the whole cohort. D) When stratified for diagnoses, GFAP in serum and NPTX2 in CSF correlated positively in PDD/DLB, while no significant correlation was found in OND, FTD, and MCI-AD. E) A significant positive correlation was found for serum GFAP and serum NfL. F) When stratified for diagnoses, a significant positive correlation was found for serum GFAP and serum NfL in OND, FTD, MCI-AD, PDD/DLB. Lines represent linear regression and grey areas represent 95% confidence intervals. CSF, Cerebrospinal fluid; GFAP, Glial fibrillary acidic protein; NPTX2, Neuronal pentraxin-2; NfL, Neurofilament light; OND, Other neurological diseases; FTD, Frontotemporal dementia, MCI-AD, Mild cognitive impairment due to Alzheimer’s disease; PDD/DLB, Lewy body dementias.CC BY-NC · PubMed Central
Fig. 5 Association between CSF and serum biomarkers. Associations between CSF and serum biomarkers were assessed using Spearman’s correlation. A) A significant strong correlation was found for CSF and serum NfL. B) CSF and serum GFAP correlated moderately in the whole cohort. C) NfL in serum and CSF correlated in all diagnostic groups. D) GFAP in serum and CSF correlated in PDD/DLB, and showed a positive trend in OND and MCI-AD. No correlation was observed in FTD. Lines represent linear regression and grey areas represent 95% confidence intervals. CSF, Cerebrospinal fluid; NfL, Neurofilament light; GFAP, Glial fibrillary acidic protein; OND, Other neurological disease; FTD, Frontotemporal dementia; MCI-AD, Mild cognitive impairment due to Alzheimer’s disease; PDD/DLB, Lewy body dementias.
Fig. 5 Association between CSF and serum biomarkers. Associations between CSF and serum biomarkers were assessed using Spearman’s correlation. A) A significant strong correlation was found for CSF and serum NfL. B) CSF and serum GFAP correlated moderately in the whole cohort. C) NfL in serum and CSF correlated in all diagnostic groups. D) GFAP in serum and CSF correlated in PDD/DLB, and showed a positive trend in OND and MCI-AD. No correlation was observed in FTD. Lines represent linear regression and grey areas represent 95% confidence intervals. CSF, Cerebrospinal fluid; NfL, Neurofilament light; GFAP, Glial fibrillary acidic protein; OND, Other neurological disease; FTD, Frontotemporal dementia; MCI-AD, Mild cognitive impairment due to Alzheimer’s disease; PDD/DLB, Lewy body dementias.CC BY-NC · PubMed Central

Verification

Claims the paper makes

18 Valid · 0 Not valid · 24 Not checked · 73 Own results and interpretations

38 more claims

Create a free account to see all 115 claims and to verify the 56 references still open.

See all claims — free account
  • Probably not a substantial claim. 55
  • It may state two separate claims as one. 25

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

5 of 5

Citations

Cites

Show all 95 references

Research works printed but not linked: 2

  1. Luscher, 2014, Frontotemporal Dementia (FTD) - even with revisited criteria a diagnostic challenge, Fortschr Neurol Psychiatr, 82, 267
  2. Benedet Al, 2021, Differencesbetween plasma and cerebrospinal fluid glial fibrillary acidicprotein levels across the Alzheimer Disease Continuum, JAMANeurol, 78, 1471

Cited by

See all 36

Metadata

Authors
Bolsewig, K., Hok-A-Hin, Y. S., Sepe, F. N., Boonkamp, L., Jacobs, D., Bellomo, G., Paoletti, F. P., Vanmechelen, E., Teunissen, C. E., Parnetti, L., & Willemse, E. A. J.
Affiliations
  • Amsterdam Neuroscience (NL)
  • Department of Clinical Chemistry, Neuro chemistry Laboratory and Biobank, Amsterdam Neuroscience, Amsterdam UMC, VU University, The Netherlands
  • University of Perugia (IT)
  • ADx NeuroSciences (BE)
Corresponding author
Bolsewig, Katharina
Venue
Journal of Alzheimer's Disease
Published
2022-10-25
Volume
90
Issue
1
Pages
363-380
ISSN
  • 1387-2877 (ISSN-L)
  • 1875-8908
OpenAlex
W4296077746
Cited by
36
References
95
Citations by year
2026: 3 · 2025: 10 · 2024: 19 · 2023: 4
FWCI
5.38
Type
journal article
Language
en
Open access
Locations
  • Journal of Alzheimer s Disease (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Pure Amsterdam UMC (publishedVersion, other-oa)
  • Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion, other-oa)
  • Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
Funders
European Commission (HORIZON2020, 860197)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
Keywords
frontotemporal dementia, differential diagnosis of dementia
MeSH terms
Pentraxins, Alzheimer Disease, Glial Fibrillary Acidic Protein, Humans, Intermediate Filaments, Biomarkers, Amyloid beta-Peptides, tau Proteins, Neurofilament Proteins, Lewy Body Disease, Frontotemporal Dementia

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Combination of Neurofilament Light, Glial Fibrillary Acidic Protein, and Neuronal Pentraxin-2 Discriminates Between Frontotemporal Dementia and Other Dementias. https://app.cochat.ai/papers/10.3233/jad-220318
The paper
Bolsewig, K., Hok-A-Hin, Y. S., Sepe, F. N., Boonkamp, L., Jacobs, D., Bellomo, G., Paoletti, F. P., Vanmechelen, E., Teunissen, C. E., Parnetti, L., & Willemse, E. A. J. (2022). A Combination of Neurofilament Light, Glial Fibrillary Acidic Protein, and Neuronal Pentraxin-2 Discriminates Between Frontotemporal Dementia and Other Dementias. Journal of Alzheimer's Disease. https://doi.org/10.3233/jad-220318

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.